MiniMed Glucose Monitor Approval Sweet As Stock Gains 30% In June
This article was originally published in The Gray Sheet
Executive Summary
FDA approval of MiniMed's continuous glucose monitoring system (CGMS) June 16 helped sweeten the company's stock price during the month.
You may also be interested in...
GlucoWatch Recommendation Conditioned On Extensive Education Program
Cygnus, Inc. should develop an "extensive education program" for both physicians and patients in the use of the firm's GlucoWatch Biographer wrist-worn semi-continuous glucose meter, members of FDA's Clinical Chemistry and Clinical Toxicology Devices Panel agreed Dec. 6 in Gaithersburg, Maryland.
GlucoWatch Recommendation Conditioned On Extensive Education Program
Cygnus, Inc. should develop an "extensive education program" for both physicians and patients in the use of the firm's GlucoWatch Biographer wrist-worn semi-continuous glucose meter, members of FDA's Clinical Chemistry and Clinical Toxicology Devices Panel agreed Dec. 6 in Gaithersburg, Maryland.
MiniMed Continuous Glucose Monitor Rollout Expanding To 30 Centers In Q4
Expanded roll-out of MiniMed's continuous glucose monitor system to twenty-one additional U.S. centers will be completed by the end of November, the firm says.